Literature DB >> 16453287

Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions.

Kunio Matsumoto1, Toshikazu Nakamura.   

Abstract

Crosstalk between carcinoma cells and host stromal cells such as fibroblasts has a great deal of influence on the invasive and metastatic behavior of cancer cells. The oncogenic action of fibroblasts has been demonstrated through genetic alterations that occur specifically in fibroblasts. Hepatocyte growth factor (HGF), a ligand for the Met receptor tyrosine kinase, plays a definitive role, particularly in the progression to invasive and metastatic cancers, predominantly as a stroma-derived paracrine mediator. Many types of cancer cells secrete molecules that enhance HGF production in fibroblasts, while fibroblast-derived HGF, in turn, is a potent stimulator of the invasion of cancer cells. Fibroblast-specific genetic alterations leading to an overexpression of HGF are associated with the development of epithelial neoplasia and invasive carcinoma. Strategies for targeting the HGF-Met axis are being pursued, in attempts to block the malignant behavior of cancers. In normal tissues, the HGF-Met axis plays diverse roles in organogenesis and in wound healing. The simile that "cancer is a never-healing wound" appears to be pertinent here. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16453287     DOI: 10.1002/ijc.21808

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  77 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

2.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

3.  Modulation of hepatocyte growth factor secretion in human female reproductive tract stromal fibroblasts by poly (I:C) and estradiol.

Authors:  Kimberly D Coleman; Mimi Ghosh; Sarah G Crist; Jacqueline A Wright; Richard M Rossoll; Charles R Wira; John V Fahey
Journal:  Am J Reprod Immunol       Date:  2011-08-23       Impact factor: 3.886

4.  Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion.

Authors:  Apaporn Menakongka; Tuangporn Suthiphongchai
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

5.  Beta-catenin signaling involves HGF-enhanced HepG2 scattering through activating MMP-7 transcription.

Authors:  Fei-Yan Pan; Sheng-Zhou Zhang; Na Xu; Fan-Li Meng; Hong-Xia Zhang; Bin Xue; Xiao Han; Chao-Jun Li
Journal:  Histochem Cell Biol       Date:  2010-07-31       Impact factor: 4.304

6.  Cancer associated fibroblasts: the dark side of the coin.

Authors:  Paolo Cirri; Paola Chiarugi
Journal:  Am J Cancer Res       Date:  2011-03-12       Impact factor: 6.166

7.  MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.

Authors:  Jessica B Casaletto; Melissa L Geddie; Adnan O Abu-Yousif; Kristina Masson; Aaron Fulgham; Antoine Boudot; Tim Maiwald; Jeffrey D Kearns; Neeraj Kohli; Stephen Su; Maja Razlog; Andreas Raue; Ashish Kalra; Maria Håkansson; Derek T Logan; Martin Welin; Shrikanta Chattopadhyay; Brian D Harms; Ulrik B Nielsen; Birgit Schoeberl; Alexey A Lugovskoy; Gavin MacBeath
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-21       Impact factor: 11.205

8.  HGF signaling regulates Claudin-3 dynamics through its C-terminal tyrosine residues.

Authors:  Floor Twiss; Michiel Oldenkamp; Annemieke Hiemstra; Houjiang Zhou; Lucrèce Matheron; Shabaz Mohammed; Johan de Rooij
Journal:  Tissue Barriers       Date:  2014-01-09

9.  EGF enhances low-invasive cancer cell invasion by promoting IMP-3 expression.

Authors:  Xianglan Zhang; Im-Hee Jung; Young Sun Hwang
Journal:  Tumour Biol       Date:  2015-09-19

Review 10.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.